Asset Purchase Agreement (Tables)

6 Months Ended

Jun. 30, 2026

Asset Purchase Agreement [Abstract]

Schedule of Development Milestones

Development Milestones			Milestone payment
First Patient Dosed in Phase 2 Initiated with Frunexian or EP-7327		$	500,000 per compound
First Patient Dosed in Phase 1 Initiated with EP-7327		$	500,000 per compound
First Patient Dosed in Phase 3 Initiated with Frunexian or EP-7327		$	1,000,000 per compound
FDA Approval of New Drug Application for Frunexian or EP-7327		$	6,000,000 per compound

Development Milestones		Milestone payment
First Patient Dosed in the First Clinical Trial with CAD-1005		$	2,000,000
First regulatory filing approval to market a pharmaceutical product for human use containing a Compound that is covered by a patent owned or licensed by Veralox (the “Product”) in the United States		$	8,000,000
First regulatory filing approval to market a Product outside the United States		$	2,000,000
Regulatory filing approval to market a Product for a subsequent indication in the United States		$	2,000,000
Regulatory filing approval to market a Product for a subsequent indication outside the United States		$	1,000,000

Schedule of Initial Purchase Price of the Assets Acquired

The following table summarizes the initial purchase price of the assets acquired:

In process research and development		$	50,000
Transaction costs			151,216
Total		$	201,216

The following table summarizes the initial purchase price of the assets acquired:

In process research and development		$	200,000
Transaction costs			131,797
Total		$	331,797